Loading stock data…
BHST
$4.18-0.03 (-0.71%)
Market ClosedLast close May 1
BioHarvest Sciences Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioHarvest Sciences Inc. Common Stock in the Consumer Defensive sector is trading at $4.18. The stock is currently near its 52-week low of $4.10, remaining 37.7% below its 200-day moving average. Technical signals show neutral RSI of 40 and bearish MACD signal, explaining why BHST maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 40) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.18
Potential Upside
5%
Whystock Fair Value$4.39
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$12.75+205.0%
Range$10.00 – $15.00
Fundamentals
BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through Nutraceuticals and Pharmaceuticals segments. The company develops botanical synthesis platform technology to produce plant cells with hi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$98.38M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-43.76%
Volume
Today's trading volume
49,837
Recent News
BioHarvest Sciences names co-founder Rakib as CEO in leadership transition
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Wednesday it has appointed co-founder Dr Zaki Rakib as CEO, consolidating leadership of its research, manufacturing, and operations under a unified structure as the botanical technology company sharpens its growth strategy. Rakib, who...
3 Stocks Estimated To Be Trading Up To 43% Below Intrinsic Value
The United States market remained flat over the last week but has experienced a significant 30% increase over the past year, with earnings forecasted to grow by 16% annually. In such an environment, identifying stocks that are trading below their intrinsic value can present opportunities for investors seeking potential gains while aligning with projected growth trends.
Ligand Pharmaceuticals And 2 Other Stocks That May Be Trading At An Estimated Discount
Over the last 7 days, the United States market has remained flat, yet it is up 30% over the past year with earnings expected to grow by 16% per annum in the coming years. In this environment, identifying stocks that may be trading at an estimated discount can provide opportunities for investors seeking value amidst a generally rising market.
April 2026's Top 3 Stocks That May Be Trading Below Estimated Fair Value
Over the last 7 days, the United States market has remained flat, yet it has experienced a significant 30% increase over the past year with earnings projected to grow by 16% annually. In this environment, identifying stocks that may be trading below their estimated fair value can present opportunities for investors seeking potential long-term gains.
3 Stocks That Might Be Undervalued By Up To 32.8%
Over the last 7 days, the United States market has remained flat, yet it has experienced a significant 30% increase over the past year with earnings forecasted to grow by 16% annually. In this environment, identifying stocks that might be undervalued can present opportunities for investors looking to capitalize on potential growth while market conditions remain favorable.